

PRODUCT MONOGRAPH  
INCLUDING PATIENT MEDICATION INFORMATION

**PrTYBOST®**  
cobicistat tablets  
150 mg, Oral  
Pharmacokinetic Enhancer

Gilead Sciences Canada, Inc.  
Mississauga, ON L5N 2W3

[www.gilead.ca](http://www.gilead.ca)

Submission Control No.: 250376

Date of Initial Authorization:  
August 27, 2013

Date of Revision: August 17, 2021

## RECENT MAJOR LABEL CHANGES

2 Contraindications	05/2020
7 Warnings and Precautions, General	05/2020

## TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

RECENT MAJOR LABEL CHANGES .....	2
PART I. HEALTH PROFESSIONAL INFORMATION.....	4
1 INDICATIONS .....	4
1.1 Pediatrics.....	4
1.2 Geriatrics .....	4
2 CONTRAINDICATIONS.....	4
4 DOSAGE AND ADMINISTRATION .....	7
4.2 Recommended Dose and Dosage Adjustment .....	7
4.5 Missed Dose .....	8
5 OVERDOSAGE.....	8
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING .....	8
7 WARNINGS AND PRECAUTIONS .....	9
7.1 Special Populations.....	11
7.1.1 Pregnant Women .....	11
7.1.2 Breast-feeding.....	12
7.1.3 Pediatrics .....	12
7.1.4 Geriatrics .....	12
7.1.5 Patients with HIV and Hepatitis B Virus Coinfection.....	12
8 ADVERSE REACTIONS .....	12
8.1 Adverse Reaction Overview.....	12
8.2 Clinical Trial Adverse Reactions.....	12
8.3 Less Common Clinical Trial Adverse Reactions .....	13
8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data.....	14
9 DRUG INTERACTIONS.....	15
9.1 Serious Drug Interactions .....	15
9.2 Drug Interaction Overview .....	16
9.3 Drug-Behavioural Interactions.....	16
9.4 Drug-Drug Interactions .....	16
9.5 Drug-Food Interactions.....	27
9.6 Drug-Herb Interactions .....	27
9.7 Drug-Laboratory Test Interactions.....	27
10 CLINICAL PHARMACOLOGY.....	28
10.1 Mechanism of Action .....	28
10.2 Pharmacodynamics.....	28

10.3 Pharmacokinetics.....	29
11 STORAGE, STABILITY AND DISPOSAL .....	30
12 SPECIAL HANDLING INSTRUCTIONS .....	30
PART II. SCIENTIFIC INFORMATION .....	32
13 PHARMACEUTICAL INFORMATION.....	32
14 CLINICAL TRIALS .....	32
14.1 Clinical Trials by Indication .....	32
In Combination with Atazanavir in HIV-1 Infected Adult Patients.....	32
15 MICROBIOLOGY .....	34
16 NON-CLINICAL TOXICOLOGY .....	35
PATIENT MEDICATION INFORMATION .....	37

## PART I. HEALTH PROFESSIONAL INFORMATION

### 1 INDICATIONS

TYBOST® (cobicistat) is an inhibitor of the cytochrome P450 3A isoenzyme indicated to increase systemic exposures of atazanavir in HIV-1 infected adult patients.

The safety and efficacy of TYBOST was evaluated in a 48 week randomized, double-blind, active-controlled Phase 3 trial in HIV-1 infected treatment-naïve adult patients comparing atazanavir/cobicistat plus emtricitabine/tenofovir disoproxil fumarate (DF) to atazanavir/ritonavir plus emtricitabine/tenofovir DF.

#### 1.1 Pediatrics

**Pediatrics (< 18 years of age):** No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

#### 1.2 Geriatrics

**Geriatrics (≥ 65 years of age):** Clinical studies of TYBOST did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from adult subjects < 65 years of age.

### 2 CONTRAINDICATIONS

TYBOST is contraindicated in patients with known hypersensitivity to any of the components of the product. For a complete listing, see the **6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING** section of the Product Monograph.

Coadministration is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events, and with drugs that are potent inducers of CYP3A due to the potential for loss of therapeutic effect. Therefore, coadministration is contraindicated with, but not limited to, the drugs listed in Table 1 (see **9.4 Drug-Drug Interactions**).

**Table 1. Drugs that are Contraindicated with TYBOST**

<b>Drug Class:</b>	<b>Drugs within class that are contraindicated with TYBOST</b>	<b>Clinical Comment</b>
Alpha 1-adrenoreceptor antagonists	alfuzosin	Potential for increased alfuzosin concentrations, which can result in hypotension.
Antianginal	ranolazine*	Potential for serious and/or life-threatening reactions.
Antiarrhythmic	dronedarone	Potential for increased dronedarone concentrations.
Anticonvulsants	carbamazepine, phenobarbital, phenytoin	Carbamazepine, a potent CYP3A inducer, decreases cobicistat plasma concentrations and that of atazanavir, which may result in loss of therapeutic effect and development of resistance.

<b>Drug Class:</b>	<b>Drugs within class that are contraindicated with TYBOST</b>	<b>Clinical Comment</b>
		Coadministration of TYBOST with carbamazepine, phenobarbital, or phenytoin is contraindicated.
Anti-gout	colchicine	Contraindicated in patients with renal and/or hepatic impairment due to potential for serious and/or life-threatening reactions
Antihistamines	astemizole*, terfenadine*	Potential for serious and/or life-threatening reactions such as cardiac arrhythmias.
Antimycobacterials	rifampin	Rifampin is a potent inducer of CYP450 metabolism. TYBOST should not be used in combination with rifampin, as this may cause significant decrease in the plasma concentration of cobicistat. This may result in loss of therapeutic effect and development of resistance to TYBOST.
Antineoplastics	irinotecan	Atazanavir inhibits UGT1A1 and may interfere with the metabolism of irinotecan, resulting in increased irinotecan toxicity.
Antipsychotics	lurasidone	Potential for serious and/or life-threatening reactions.
Beta 2-adrenoceptor agonist	salmeterol	Coadministration of salmeterol with TYBOST may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations, and sinus tachycardia.
Benzodiazepines	orally administered midazolam*, triazolam	Triazolam and orally administered midazolam are extensively metabolized by CYP3A4. Coadministration of triazolam or orally administered midazolam with TYBOST may cause large increases in the concentration of these benzodiazepines. The potential exists for serious and/or life-threatening events such as prolonged or increased sedation or respiratory depression.
Direct oral anticoagulants	apixaban, rivaroxaban	Apixaban and rivaroxaban are primarily metabolized by CYP3A4 and transported by P-gp. Coadministration with TYBOST may result in increased plasma concentrations of apixaban or rivaroxaban, which may lead to an increased bleeding risk.

<b>Drug Class:</b>	<b>Drugs within class that are contraindicated with TYBOST</b>	<b>Clinical Comment</b>
Ergot derivatives	dihydroergotamine, ergonovine, ergotamine, methylergonovine*	Potential for serious and/or life-threatening events such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.
Hepatitis C Direct-Acting Antiviral	elbasvir/grazoprevir	Contraindicated because of the potential increase in the risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations caused by OATP1B1/3 inhibition by atazanavir.
Herbal products	St. John's wort ( <i>Hypericum perforatum</i> )	Patients taking TYBOST should not use products containing St. John's wort because coadministration may result in reduced plasma concentrations of cobicistat. This may result in loss of therapeutic effect and development of resistance.
HMG CoA reductase inhibitors	lovastatin, simvastatin	Potential for serious reactions such as myopathy, including rhabdomyolysis.
Hormonal Contraceptives	drospirenone/ ethinyl estradiol	Potential for increased drospirenone concentrations, which can result in hyperkalemia.
Microsomal triglyceride transfer protein inhibitor	lomitapide	Potential for increased lomitapide concentrations which may result in markedly increased transaminases.
Neuroleptics	pimozide	Potential for serious and/or life-threatening events such as cardiac arrhythmias.
Non-nucleoside Reverse Transcriptase Inhibitor	nevirapine	Nevirapine substantially decreases atazanavir exposure which may result in loss of therapeutic effect and development of resistance. Potential risk for nevirapine-associated adverse reactions due to increased nevirapine exposures.
Phosphodiesterase-5 (PDE-5) inhibitors	sildenafil <sup>†</sup>	A safe and effective dose in combination with TYBOST has not been established for sildenafil (Revatio <sup>®</sup> ) when used for the treatment of pulmonary hypertension. There is increased potential for sildenafil-associated adverse events (which include visual disturbances, hypotension, priapism, and syncope).
Protease Inhibitor	indinavir*	Both atazanavir and indinavir are associated with indirect (unconjugated) hyperbilirubinemia.

- \* Not marketed in Canada.
- † For the treatment of pulmonary arterial hypertension.

## 4 DOSAGE AND ADMINISTRATION

### 4.2 Recommended Dose and Dosage Adjustment

TYBOST must be coadministered with atazanavir and with food. The recommended dose of TYBOST and that of the coadministered protease inhibitor, atazanavir, are presented in Table 2. As TYBOST is used in combination with atazanavir, also consult the atazanavir Product Monograph.

**Table 2. Recommended Dosing Regimens**

Dose of TYBOST	Dose of recommended HIV-1 protease inhibitor
150 mg once daily	Atazanavir 300 mg once daily

#### Pediatrics (< 18 years of age)

No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

#### Geriatrics (> 65 years of age)

Insufficient data are available on which to make a dose recommendation for patients over 65 years of age.

#### Renal Impairment

No dose adjustment of TYBOST is required in patients with renal impairment, including those with severe renal impairment.

TYBOST should not be initiated as part of a regimen containing emtricitabine, lamivudine, tenofovir disoproxil fumarate or adefovir in patients who have an estimated creatinine clearance below 70 mL/min since dose adjustment of these drugs is required below 50 mL/min and such dose adjustments have not been established in combination with TYBOST (see **7 WARNINGS AND PRECAUTIONS, Renal, 8 ADVERSE REACTIONS, 10 CLINICAL PHARMACOLOGY, Effect on Serum Creatinine, and 14 CLINICAL TRIALS**).

#### Hepatic Impairment

No dose adjustment of TYBOST is required in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. TYBOST has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) (see **10 CLINICAL PHARMACOLOGY, Hepatic Insufficiency**).

#### 4.5 Missed Dose

If a patient misses a dose of TYBOST within 12 hours of the time it is usually taken, the patient should take TYBOST with a meal as soon as possible, and then take the next dose of TYBOST at the regularly scheduled time with atazanavir.

If a patient misses a dose of TYBOST by more than 12 hours, the patient should not take the missed dose, but wait and take the next dose of TYBOST with atazanavir at the regularly scheduled time.

If the patient misses a dose of atazanavir refer to the atazanavir Product Monograph.

If a patient misses a dose of TYBOST and atazanavir, TYBOST should be taken at the same time as atazanavir, with food. For atazanavir dosing refer to the atazanavir Product Monograph.

#### 5 OVERDOSAGE

If overdose occurs the patient must be monitored for evidence of toxicity. Treatment of overdose with TYBOST consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient.

Limited clinical experience is available at doses higher than the therapeutic dose of cobicistat. In two studies, a single dose of cobicistat 400 mg was administered to a total of 60 healthy subjects. No severe adverse reactions were reported. The effects of higher doses are not known. Since cobicistat is highly bound to plasma proteins, it is unlikely that it will be significantly removed by hemodialysis or peritoneal dialysis.

The Product Monograph of the coadministered product atazanavir should also be consulted.

For management of a suspected drug overdose, contact your regional Poison Control Centre.
---

#### 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

**Table 3. Dosage Forms, Strengths, Composition and Packaging**

Route of Administration	Dosage Form/Strength/Composition	Non-medicinal Ingredients
Oral	Tablet 150 mg cobicistat	Silicon dioxide, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. The tablets are coated with a coating material containing polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide, sunset yellow FCF (FD&C Yellow #6) aluminum lake, and iron oxide yellow.

TYBOST tablets are orange, round, biconvex, and film-coated, debossed with “GSI” on one side and plain-faced on the other side. Each bottle contains 30 tablets and a silica gel desiccant and closed with a child-resistant closure.



## 7 WARNINGS AND PRECAUTIONS

### General

Cobicistat is a potent CYP3A inhibitor. Initiating treatment with TYBOST in patients receiving medications metabolized by CYP3A or initiating medications metabolized by CYP3A in patients already receiving TYBOST may result in increased plasma concentration of these concomitant medications. Higher plasma concentrations of concomitant medications can result in increased or prolonged therapeutic or adverse effects, potentially leading to serious and/or life-threatening events. Coadministration of TYBOST with drugs that have active metabolite(s) formed by CYP3A may result in reduced plasma concentrations of these active metabolite(s), potentially leading to loss of therapeutic effect. Coadministration of TYBOST with drugs that induce CYP3A may result in decreased plasma concentration of cobicistat and consequently that of the concomitant medication, leading to loss of therapeutic effect and possible development of resistance. The potential for drug-drug interactions must be considered prior to and during therapy with TYBOST. Review of other medications taken by patients and monitoring of patients for adverse effects is recommended during therapy with TYBOST (see **2 CONTRAINDICATIONS** and **9.4 Drug-Drug Interactions**).

TYBOST is a CYP3A inhibitor and a CYP3A substrate, and therefore must not be used concurrently with products containing ritonavir or other potent CYP3A inhibitors due to similar effects of cobicistat and ritonavir on CYP3A.

Due to inhibition of CYP3A4 by TYBOST, coadministration of TYBOST with quetiapine may result in increased quetiapine concentrations. Serious and/or life-threatening quetiapine-related adverse reactions, including severe sedation and coma, have been reported for concomitant use of potent CYP3A4 inhibitors and quetiapine. TYBOST should not be used in combination with quetiapine. If coadministration is necessary, reduce the quetiapine dose, and monitor for quetiapine-associated adverse reactions as recommended in the quetiapine Product Monograph (see **9 DRUG INTERACTIONS**).

**TYBOST must not be used concurrently with products containing cobicistat (ie, the fixed-dose combination product STRIBILD® [elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate], GENVOYA® [elvitegravir/cobicistat/ emtricitabine/tenofovir alafenamide], Prezcofix® [cobicistat/darunavir] or Symtuza® [darunavir/cobicistat/emtricitabine/tenofovir alafenamide]).**

TYBOST is a pharmacokinetic enhancer of atazanavir. Prescribers should consult the complete atazanavir Product Monograph for a description of additional contraindicated drugs, significant drug-drug interactions, and warnings and precautions associated with atazanavir.

Dosing recommendations have only been established for use of TYBOST with atazanavir once daily. TYBOST should not be used as a pharmacokinetic enhancer to boost any other HIV-1 protease inhibitor since dosing recommendations for such coadministrations have not been established (see **4 DOSAGE AND ADMINISTRATION**).

TYBOST coadministered with atazanavir should not be used in combination with another antiretroviral that requires boosting (ie, another protease inhibitor), since dosing recommendations for such combination have not been established.

## **Carcinogenesis and Mutagenesis**

See **16 NON-CLINICAL TOXICOLOGY** section.

## **Endocrine and Metabolism**

### ***Fat Redistribution***

Redistribution/accumulation of body fat (lipodystrophy) including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and “cushingoid appearance” have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.

## **Hepatic/Biliary/Pancreatic**

### ***Hepatic Impairment***

Limited data on the use of TYBOST in patients with mild or moderate hepatic impairment (Child-Pugh Class A and B, respectively) suggests that no dose adjustment of TYBOST is required in these patients. No pharmacokinetic or safety data are available regarding the use of TYBOST in patients with severe hepatic impairment (Child-Pugh Class C). Therefore, TYBOST is not recommended for use in patients with severe hepatic impairment.

Cobicistat is primarily metabolized and eliminated by the liver. A study of the pharmacokinetics of cobicistat-boosted elvitegravir in non-HIV-1 infected subjects with moderate hepatic impairment (Child-Pugh Class B) and healthy subjects did not reveal any clinically relevant differences in elvitegravir or cobicistat pharmacokinetics. The pharmacokinetics of cobicistat has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).

The safety and efficacy of TYBOST have not been studied specifically in patients with underlying liver disorders. Patients with chronic hepatitis B or C and treated with antiretroviral therapy are at increased risk for severe and potentially fatal hepatic adverse events. In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products (see **7.1 Special Populations**).

## **Immune**

### ***Immune Reconstitution Inflammatory Syndrome***

Immune reconstitution inflammatory syndrome has been reported in patients treated with combination antiretroviral therapy. During the initial phase of combination antiretroviral treatment, patients responding to antiretroviral therapy may develop an inflammatory response to indolent or residual opportunistic infections (such as *Mycobacterium avium* complex (MAC) infection, cytomegalovirus (CMV) infection, *Pneumocystis jiroveci* pneumonia (PCP), or tuberculosis (TB)), which may necessitate further evaluation and treatment.

Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiation of treatment.

## Renal

### ***Effects on Serum Creatinine***

TYBOST has been shown to decrease estimated creatinine clearance due to inhibition of tubular secretion of creatinine without affecting actual renal glomerular function. This effect should be considered when interpreting changes in estimated creatinine clearance in patients initiating TYBOST (particularly in patients with medical conditions or receiving drugs needing monitoring with estimated creatinine clearance). Dosing recommendations are not available for drugs that require dosing adjustment for renal impairment with the use of TYBOST (see **4.2 Recommended Dose and Dosage Adjustment**). Consider alternative medications that do not require dosing adjustments.

Prior to initiating therapy with TYBOST, assess estimated creatinine clearance. Although TYBOST may cause modest increases in serum creatinine and modest declines in estimated creatinine clearance without affecting renal glomerular function, patients who experience a confirmed increase in serum creatinine of greater than 0.4 mg per dL from baseline should be closely monitored for renal safety.

### ***New Onset or Worsening Renal Impairment When Used with Tenofovir Disoproxil Fumarate***

Renal impairment, including cases of acute renal failure and Fanconi syndrome, has been reported when TYBOST is used in an antiretroviral regimen that contains tenofovir disoproxil fumarate (tenofovir DF).

- Do not initiate TYBOST as part of a regimen containing tenofovir DF in patients who have an estimated creatinine clearance below 70 mL/min because dose adjustment of tenofovir DF is required below 50 mL/min and such dose adjustments have not been established for coadministration with TYBOST.
- Document urine glucose and urine protein at baseline and perform routine monitoring of estimated creatinine clearance, urine glucose, and urine protein during treatment when TYBOST is used with tenofovir DF.
- Measure serum phosphorus in patients with or at risk for renal impairment.
- Avoid use of TYBOST with tenofovir DF in combination with concomitant or recent use of a nephrotoxic agent.

## **7.1 Special Populations**

### **7.1.1 Pregnant Women**

There are not sufficient data to recommend the routine initiation of TYBOST in women during pregnancy. TYBOST should not be used in pregnant women unless the potential benefits outweigh the potential risks to the fetus and mother. Lower exposures of cobicistat have been reported during pregnancy compared to postpartum. Closely monitor viral load during pregnancy, if TYBOST is continued to be used in an antiretroviral regimen.

***Antiretroviral Pregnancy Registry:*** To monitor fetal outcomes of pregnant women exposed to ART (antiretroviral therapy) including TYBOST, an Antiretroviral Pregnancy Registry has been established. Healthcare providers are encouraged to register patients, <http://www.apregistry.com>

Telephone: (800) 258-4263  
Fax: (800) 800-1052

### 7.1.2 Breast-feeding

**HIV-1 infected mothers should not breast-feed their infants to avoid risking postnatal transmission of HIV.** Studies in rats have demonstrated that cobicistat is secreted in milk. It is not known whether cobicistat is excreted in human milk. Because of both the potential for HIV transmission and the potential for serious adverse reactions in nursing infants, **mothers should be instructed not to breast-feed if they are receiving TYBOST.**

### 7.1.3 Pediatrics

**Pediatrics (< 18 years of age):** No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

### 7.1.4 Geriatrics

**Geriatrics (≥ 65 years of age):** Clinical studies of TYBOST did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than adult patients < 65 years of age. In general, dose selection for elderly patients should be cautious, keeping in mind the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

### 7.1.5 Patients with HIV and Hepatitis B Virus Coinfection

The pharmacokinetics of TYBOST have not been fully evaluated in subjects coinfecting with hepatitis B and/or C virus.

## 8 ADVERSE REACTIONS

### 8.1 Adverse Reaction Overview

The safety of TYBOST has been established from a Phase 3, randomized, active-controlled clinical trial (Study 114), in which 692 HIV-1 infected, antiretroviral treatment-naïve adults received TYBOST-boosted atazanavir + TRUVADA (N=344) or ritonavir-boosted atazanavir + TRUVADA (N=348) for at least 48 weeks. Adverse reactions for TYBOST-boosted atazanavir were consistent with the safety profile of ritonavir-boosted atazanavir.

### 8.2 Clinical Trial Adverse Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

See Table 4 for the frequency of treatment-emergent adverse reactions (Grade 2-4) occurring in at least 2% of subjects receiving TYBOST-boosted atazanavir + TRUVADA in Study 114. The most common adverse reactions (incidence greater than or equal to 5%) occurring in subjects receiving TYBOST-boosted atazanavir + TRUVADA was jaundice, consistent with the safety profile of atazanavir.

**Table 4. Treatment-Emergent Adverse Drug Reactions<sup>a</sup> (Grades 2-4) Reported in  $\geq 2\%$  of Subjects Receiving TYBOST-boosted Atazanavir + TRUVADA in Study 114 (Week 48 analysis)**

	TYBOST-boosted Atazanavir + TRUVADA	Ritonavir-boosted Atazanavir + TRUVADA
	N=344	N=348
EYE DISORDERS		
Ocular icterus	3%	1%
GASTROINTESTINAL DISORDERS		
Nausea	2%	2%
HEPATOBIILIARY DISORDERS		
Jaundice	6%	3%
Hyperbilirubinaemia	4%	3%
SKIN AND SUBCUTANEOUS TISSUE DISORDERS		
Rash <sup>b</sup>	4%	3%

- a. Frequencies of adverse reactions are based on Grade 2-4 treatment-emergent adverse events, attributed to study drugs.
- b. Rash event includes rash, rash generalized, rash maculo-papular, rash macular, and rash morbilliform.

### 8.3 Less Common Clinical Trial Adverse Reactions

Treatment-emergent adverse drug reactions of at least moderate severity ( $\geq$  Grade 2) occurring in less than 2% of subjects receiving TYBOST with atazanavir + TRUVADA in Study 114 are listed below.

*Ear and Labyrinth Disorders:* vertigo

*Gastrointestinal Disorders:* diarrhea, vomiting, constipation, abdominal pain, hyperchlorhydria

*General Disorders and Administration Site Conditions:* fatigue, asthenia

*Immune System Disorders:* drug hypersensitivity

*Metabolism and Nutrition Disorders:* increased appetite, decreased appetite, diabetes mellitus, hyperlipidaemia, hypertriglyceridaemia

*Musculoskeletal and Connective Tissue Disorders:* back pain, myalgia, rhabdomyolysis

*Nervous System Disorders:* headache

*Pregnancy, Puerperium and Perinatal Conditions:* abortion spontaneous

*Psychiatric Disorders:* insomnia, abnormal dreams, depression, affective disorder

*Renal and Urinary Disorders:* Fanconi syndrome acquired, nephrolithiasis, renal impairment,

haematuria, hydronephrosis, nephropathy, renal colic

*Reproductive System and Breast Disorders:* premenstrual syndrome

*Skin and Subcutaneous Tissue Disorders:* dermatitis allergic, eosinophilic pustular folliculitis, hyperhidrosis, pruritus generalized

#### 8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

##### Clinical Trial Findings

The frequency of treatment-emergent laboratory abnormalities (Grades 3-4) occurring in at least 1% of subjects receiving TYBOST-boosted atazanavir + TRUVADA in Study 114 are presented in Table 5.

**Table 5. Laboratory Abnormalities (Grades 3-4) Reported in  $\geq 1\%$  of Subjects Receiving TYBOST-boosted atazanavir + TRUVADA in Study 114 (Week 48 analysis)**

Laboratory Parameter Abnormality	TYBOST-boosted Atazanavir + TRUVADA	Ritonavir-boosted Atazanavir + TRUVADA
	N=344	N=348
Total Bilirubin ( $> 2.5 \times$ ULN)	65%	57%
Creatine Kinase ( $\geq 10.0 \times$ ULN)	6%	6%
Serum Amylase <sup>a</sup> ( $> 2.0 \times$ ULN)	3%	2%
ALT ( $> 5.0 \times$ ULN)	3%	2%
Urine RBC (Hematuria) ( $> 75$ RBC/HPF)	3%	2%
Neutrophils ( $< 750/\text{mm}^3$ )	2%	1%
AST ( $> 5.0 \times$ ULN)	3%	2%
GGT ( $> 5.0 \times$ ULN)	2%	1%
Serum Glucose ( $> 250$ mg/dL)	2%	1%
Urine Glucose (+4)	2%	1%

a. For subjects with serum amylase  $> 1.5 \times$  upper limit of normal, lipase test was also performed. The frequency of increased lipase (Grade 3-4) occurring in TYBOST-boosted atazanavir plus TRUVADA and ritonavir-boosted atazanavir plus TRUVADA treatment groups was 5% (2/38) and 4% (1/28), respectively.

In addition to the laboratory abnormalities listed in Table 5 creatinine renal clearance decreased and glomerular filtration rate abnormal ( $\geq$  Grade 2) were reported in less than 2% of subjects receiving TYBOST + TRUVADA in Study 114.

TYBOST has been shown to decrease estimated creatinine clearance due to inhibition of tubular secretion of creatinine without affecting actual renal glomerular function. An increase in serum creatinine due to TYBOST's inhibitory effect generally does not exceed 0.4 mg per dL (35.36  $\mu\text{mol/L}$ ) from baseline. In Study 114, decreases in estimated creatinine clearance

occurred early in treatment with TYBOST, after which they stabilized. The mean ( $\pm$  SD) change in estimated glomerular filtration rate by Cockcroft-Gault method (eGFR<sub>CG</sub>) after 48 weeks of treatment was  $-13.4 \pm 15.2$  mL/min in the TYBOST-boosted atazanavir + TRUVADA group and  $-8.7 \pm 14.5$  mL/min in the ritonavir-boosted atazanavir + TRUVADA group (see **10 CLINICAL PHARMACOLOGY, Effect on Serum Creatinine**).

## Serum Lipids

Changes from baseline in total cholesterol, HDL-cholesterol, LDL-cholesterol, and triglycerides are presented in Table 6.

**Table 6. Lipid Values, Mean Change from Baseline, Reported in Subjects Receiving TYBOST-boosted atazanavir + TRUVADA or Ritonavir-boosted atazanavir + TRUVADA in Study 114 (Week 48 analysis)**

	TYBOST-boosted Atazanavir + TRUVADA		Ritonavir-boosted Atazanavir + TRUVADA	
	Baseline	Week 48	Baseline	Week 48
	mg/dL	Change from baseline <sup>a</sup>	mg/dL	Change from baseline <sup>a</sup>
Total Cholesterol (fasted)	164 [N=323]	+ 5 [N=278]	166 [N=328]	+ 9 [N=287]
HDL-cholesterol (fasted)	43 [N=322]	+ 4 [N=277]	43 [N=328]	+ 3 [N=287]
LDL-cholesterol (fasted)	103 [N=322]	+ 6 [N=278]	104 [N=328]	+ 8 [N=288]
Triglycerides (fasted)	126 [N=323]	+ 19 [N=278]	132 [N=328]	+ 32 [N=287]

a. The change from baseline is the mean of within-patient changes from baseline for patients with both baseline and Week 48 values.

## 9 DRUG INTERACTIONS

### 9.1 Serious Drug Interactions

#### Serious Drug Interactions

Cobicistat is a strong inhibitor of cytochrome P450 (CYP3A) and a CYP3A substrate. Coadministration of TYBOST with drugs that are primarily metabolized by CYP3A may result in increased plasma concentrations of such drugs, which may lead to serious and/or life-threatening events. Coadministration of TYBOST with drugs that have active metabolite(s) formed by CYP3A may result in reduced plasma concentrations of these active metabolite(s). Drugs that induce CYP3A activity may decrease plasma concentration of cobicistat and consequently that of atazanavir being boosted, leading to loss of therapeutic effect and possible development of resistance (see **7 WARNINGS AND PRECAUTIONS, 2 CONTRAINDICATIONS, and 9 DRUG INTERACTIONS Table 7 – Established and Other Potentially Significant Drug Interactions**).

## 9.2 Drug Interaction Overview

### Effect of Cobicistat on the Pharmacokinetics of Concomitant Drugs

Coadministration with other CYP3A substrates may require a dose adjustment or additional monitoring as shown in Table 7. Coadministration of TYBOST with drugs that have active metabolite(s) formed by CYP3A may result in reduced plasma concentrations of these active metabolite(s) (see **7 WARNINGS AND PRECAUTIONS**).

Cobicistat is a weak inhibitor of CYP2D6. Cobicistat is not expected to inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9 or CYP2C19. Cobicistat is not expected to induce CYP1A2, CYP3A4, CYP2C9, CYP2C19, UGT1A1, or MDR1.

The transporters that cobicistat inhibits include p-glycoprotein (P-gp), BCRP, OATP1B1, and OATP1B3. Thus, coadministration of TYBOST with drugs that are primarily metabolized by CYP3A or CYP2D6, or are substrates of P-gp, BCRP, OATP1B1, or OATP1B3 may result in increased plasma concentrations of such drugs.

## 9.3 Drug-Behavioural Interactions

Interactions of TYBOST with individual behavioural risks have not been established.

## 9.4 Drug-Drug Interactions

### Established and Other Potentially Significant Drug Interactions

Table 7 provides dosing recommendations as a result of drug interactions with TYBOST. These recommendations are based on either drug interactions studies or predicted interactions due to the expected magnitude of interaction and potential for serious and/or life-threatening events or loss of efficacy. The table includes potentially significant interactions, but is not all inclusive (see **9 DRUG INTERACTIONS, Assessment of Drug Interactions, Table 8 –Table 9**).

For additional drug-drug interactions with atazanavir, consult the atazanavir Product Monograph when using TYBOST.

**Table 7. Established and Other Potentially Significant<sup>a</sup> Drug Interactions**

Concomitant Drug Class: Drug Name	Effect on Concentration <sup>b</sup>	Clinical Comment
<b>Antiretroviral Agents: Nucleoside Reverse Transcriptase Inhibitors</b>		
didanosine	↔ didanosine ↔ cobicistat	Coadministration of didanosine buffered tablets is expected to decrease atazanavir plasma concentration. Consult the atazanavir Product Monograph for atazanavir dosing recommendation when used concomitantly with didanosine.
tenofovir disoproxil fumarate	↑ tenofovir ↔ cobicistat	Coadministration of tenofovir disoproxil fumarate with TYBOST is expected to increase tenofovir plasma concentration. This increase is not expected to be clinically relevant and does



Concomitant Drug Class: Drug Name	Effect on Concentration <sup>b</sup>	Clinical Comment
		not necessitate dose adjustment of tenofovir disoproxil fumarate.
<b>Antiretroviral Agents: Non-nucleoside Reverse Transcriptase Inhibitors</b>		
delavirdine	↑ cobicistat ↑ delavirdine	Coadministration of delavirdine and TYBOST may increase delavirdine and/or cobicistat plasma concentration. The appropriate dose of delavirdine in combination with atazanavir/cobicistat has not been established. Coadministration is not recommended.
efavirenz	↓ cobicistat	Coadministration of efavirenz and TYBOST is expected to decrease cobicistat plasma concentration and consequently that of atazanavir, which may result in loss of therapeutic effect and development of resistance. Coadministration is not recommended.
etravirine	↓ cobicistat	Coadministration of etravirine and TYBOST is expected to decrease cobicistat plasma concentration and consequently that of atazanavir, which may result in loss of therapeutic effect and development of resistance. Coadministration is not recommended.
rilpivirine	↑ rilpivirine ↔ cobicistat	Coadministration of rilpivirine and TYBOST is expected to increase the plasma concentration of rilpivirine. Rilpivirine is not expected to affect the plasma concentration of cobicistat. No dose adjustment of rilpivirine is required when coadministered with atazanavir/cobicistat.
<b>Antiretroviral Agents: CCR5 Antagonists</b>		
maraviroc	↑ maraviroc	Maraviroc is a substrate of CYP3A and its plasma concentration increases when coadministered with potent CYP3A inhibitors. When coadministering maraviroc and atazanavir/cobicistat, patients should receive maraviroc 150 mg twice daily. For further details, see the maraviroc Product Monograph.
<b>Other Agents:</b>		
<b>Acid Reducing Agents:</b> Antacids (eg. aluminum and magnesium hydroxide)	↔ cobicistat ↓ antacids	No dose adjustment of TYBOST is required when coadministered with antacids. Concomitant use of antacids, including buffered medications, is expected to decrease atazanavir plasma concentration. Consult the atazanavir Product Monograph for atazanavir dosing recommendation when used concomitantly with acid-reducing agents.

<b>Concomitant Drug Class: Drug Name</b>	<b>Effect on Concentration<sup>b</sup></b>	<b>Clinical Comment</b>
<b>Analeptics:</b> modafinil	↓ cobicistat	Coadministration of modafinil, a CYP3A inducer, may decrease cobicistat plasma concentrations and consequently that of atazanavir, which may result in loss of therapeutic effect and development of resistance. Alternative analeptics should be considered.
<b>Antiarrhythmics:</b> amiodarone bepridil* disopyramide flecainide systemic lidocaine mexiletine propafenone quinidine	↑ antiarrhythmics	Concentrations of these antiarrhythmic drugs may be increased when coadministered with TYBOST. Caution is warranted and clinical monitoring is recommended upon coadministration of these agents with TYBOST.
digoxin	↑ digoxin	The peak concentration of digoxin increases when coadministered with TYBOST. The lowest dose of digoxin should initially be prescribed. The serum digoxin concentrations should be monitored and used for titration of digoxin dose to obtain the desired clinical effects.
<b>Antibacterials:</b> clarithromycin	↑ clarithromycin ↑ cobicistat ↓ 14-OH clarithromycin	Concentrations of clarithromycin may increase upon coadministration of TYBOST. Increased concentrations of clarithromycin may cause QTc prolongations; therefore, a dose reduction of clarithromycin by 50% should be considered when it is coadministered with atazanavir /TYBOST. In addition, concentrations of the active metabolite 14-OH clarithromycin are significantly reduced; consider alternative therapy for indications other than infections due to <i>Mycobacterium avium</i> complex.  Coadministration of clarithromycin and TYBOST has not been studied. Consult the atazanavir Product Monograph for further information when these TYBOST-boosted agents are used concomitantly with clarithromycin.
<b>Anticancer Agents:</b> dasatinib nilotinib vinblastine vincristine	↑ anticancer agents	Concentrations of these drugs may increase when coadministered with TYBOST resulting in the potential for increased adverse events usually associated with these anticancer agents.  A decrease in the dosage or an adjustment of the dosing interval of dasatinib and nilotinib may be necessary for patients requiring coadministration with strong CYP3A inhibitors such as TYBOST. Consult the dasatinib and

Concomitant Drug Class: Drug Name	Effect on Concentration <sup>b</sup>	Clinical Comment
		nilotinib Product Monographs for dosing instructions.
<p><b>Anticoagulants:</b> warfarin</p> <p>Direct Oral Anticoagulants (DOACs):</p> <p>apixaban rivaroxaban dabigatran edoxaban</p>	<p>↑ or ↓ warfarin</p> <p>↑ DOACs</p>	<p>Concentrations of warfarin may be affected upon coadministration with TYBOST. It is recommended that the international normalized ratio (INR) be monitored upon coadministration with TYBOST.</p> <p>DOACs are primarily metabolized by CYP3A4 and/or transported by P-gp. Coadministration with TYBOST may result in increased plasma concentrations of the DOAC, which may lead to an increased bleeding risk.</p> <p>Coadministration of a DOAC affected by both P-gp and CYP3A4, including apixaban and rivaroxaban, is contraindicated with TYBOST.</p> <p>Clinical monitoring and/or dose adjustment is recommended when a DOAC transported by P-gp, including dabigatran or edoxaban, is coadministered with TYBOST. Refer to the Product Monograph of the coadministered DOAC.</p>
<p><b>Anticonvulsants:</b> carbamazepine oxcarbazepine phenobarbital phenytoin</p> <p>clonazepam ethosuximide</p>	<p>↓ cobicistat</p> <p>↑ clonazepam ↑ ethosuximide</p>	<p>Carbamazepine, a potent CYP3A inducer, decreases cobicistat plasma concentrations and that of atazanavir, which may result in loss of therapeutic effect and development of resistance. Coadministration of TYBOST with carbamazepine, phenobarbital, or phenytoin is contraindicated.</p> <p>Coadministration of oxcarbazepine, a CYP3A inducer, may decrease cobicistat plasma concentrations and consequently that of atazanavir, which may result in loss of therapeutic effect and development of resistance. Alternative anticonvulsants should be considered.</p> <p>Concentrations of clonazepam and ethosuximide may be increased when coadministered with TYBOST. Clinical monitoring is recommended upon coadministration with TYBOST.</p>
<p><b>Antidepressants:</b> Selective Serotonin Reuptake Inhibitors (SSRIs) desipramine trazodone</p>	<p>↑ SSRIs ↑ desipramine ↑ trazodone</p>	<p>Concentrations of these antidepressant agents may be increased when coadministered with TYBOST. Dose titration may be required for most drugs of the SSRI class.</p> <p>The concentration of desipramine is increased when coadministered with TYBOST.</p> <p>Concentrations of trazodone may increase upon coadministration with TYBOST. If trazodone or</p>

Concomitant Drug Class: Drug Name	Effect on Concentration <sup>b</sup>	Clinical Comment
		desipramine is used with TYBOST, the combination should be used with caution, and a lower dose of trazadone or desipramine should be considered.
<b>Antifungals:</b> itraconazole ketoconazole voriconazole	↑ antifungals ↑ cobicistat	Concentrations of ketoconazole, itraconazole, and/or cobicistat may increase with coadministration of TYBOST. When administering with TYBOST, the maximum daily dose of ketoconazole and itraconazole should not exceed 200 mg /day. Concentrations of voriconazole may be increased when coadministered with TYBOST. Clinical monitoring may be needed upon coadministration with TYBOST.
<b>Antimycobacterial:</b> rifabutin rifapentine*	↑ rifabutin cobicistat: effects unknown	The recommended dosage regimen for rifabutin should be adjusted to 150 mg every other day. Monitor for rifabutin associated adverse reactions including neutropenia and uveitis.
<b>Antiplatelets:</b> clopidogrel prasugrel	↓ clopidogrel active metabolite  ↔ prasugrel active metabolite	Coadministration of clopidogrel with cobicistat is expected to decrease clopidogrel active metabolite plasma concentrations, which may reduce the antiplatelet activity of clopidogrel. Coadministration of clopidogrel with TYBOST is not recommended.  TYBOST is not expected to have a clinically relevant effect on plasma concentrations of the active metabolite of prasugrel.
<b>Antipsychotics:</b> quetiapine	↑ quetiapine	TYBOST should not be used in combination with quetiapine. Due to CYP3A4 inhibition by TYBOST, concentrations of quetiapine are expected to increase, which can result in serious and/or life-threatening adverse reactions. If coadministration is necessary, monitoring and quetiapine dose reduction may be required (see <b>7 WARNINGS AND PRECAUTIONS, General</b> ).
<b>Beta-Blockers:</b> metoprolol timolol	↑ beta-blockers	Concentrations of beta-blockers may be increased when coadministered with TYBOST. Clinical monitoring is recommended and a dose reduction may be necessary when these agents are coadministered with TYBOST.

<b>Concomitant Drug Class: Drug Name</b>	<b>Effect on Concentration<sup>b</sup></b>	<b>Clinical Comment</b>
<b>Calcium Channel Blockers:</b> amlodipine diltiazem felodipine nifedipine* nifedipine verapamil	↑ calcium channel blockers	Concentrations of calcium channel blockers may be increased when coadministered with TYBOST. Caution is warranted and clinical monitoring is recommended upon coadministration with TYBOST.
<b>Systemic Corticosteroids:</b> dexamethasone (oral)	↓ cobicistat	Coadministration of dexamethasone, a CYP3A inducer, may significantly decrease cobicistat plasma concentrations and consequently that of atazanavir, which may result in loss of therapeutic effect and development of resistance.  Alternative corticosteroids should be considered.
<b>Corticosteroids:</b> betamethasone budesonide dexamethasone fluticasone mometasone triamcinolone	↑ corticosteroids	Coadministration of TYBOST with corticosteroids that are sensitive to CYP3A inhibition can increase the risk for Cushing's syndrome and adrenal suppression, which have been reported during postmarketing use of cobicistat-containing products.  Coadministration of corticosteroids sensitive to CYP3A inhibition and TYBOST is not recommended unless the potential benefit to the patient outweighs the risks.  Alternative corticosteroids which are less dependent on CYP3A metabolism should be considered, particularly for long-term use.
<b>Endothelin Receptor Antagonists:</b> bosentan	↑ bosentan ↓ cobicistat	Bosentan is metabolized by CYP3A4 and is an inducer of CYP3A4. Coadministration of bosentan with TYBOST may lead to decreased cobicistat plasma concentrations and consequently that of atazanavir, which may result in loss of therapeutic effect and development of resistance.  Coadministration of bosentan in patients on atazanavir/TYBOST: In patients who have been receiving TYBOST for at least 10 days, start bosentan at 62.5 mg once daily or every other day based upon individual tolerability.  Coadministration of atazanavir/TYBOST in patients on bosentan: Discontinue use of bosentan at least 36 hours prior to initiation of

<b>Concomitant Drug Class: Drug Name</b>	<b>Effect on Concentration<sup>b</sup></b>	<b>Clinical Comment</b>
		atazanavir/TYBOST. After at least 10 days following the initiation of atazanavir/TYBOST, resume bosentan at 62.5 mg once daily or every other day based upon individual tolerability.
<b>H<sub>2</sub>-Receptor Antagonists:</b> famotidine	↔ cobicistat	No dose adjustment of cobicistat is required when atazanavir/cobicistat is coadministered with H <sub>2</sub> -receptor antagonists. H <sub>2</sub> -receptor antagonists are expected to decrease atazanavir plasma concentration. Consult the atazanavir Product Monograph for atazanavir dosing recommendation when used concomitantly with H <sub>2</sub> -receptor antagonists.
<b>Hepatitis C Virus (HCV) Protease Inhibitors:</b> boceprevir*	Effect on boceprevir and/or cobicistat unknown	No data are available to recommend appropriate doses of boceprevir when coadministered with atazanavir/cobicistat. Coadministration of TYBOST with boceprevir is not recommended.
<b>HMG-CoA Reductase Inhibitors:</b> atorvastatin rosuvastatin	↑ atorvastatin ↑ rosuvastatin	Concentrations of atorvastatin or rosuvastatin may be increased when coadministered with atazanavir/cobicistat. Consult the atazanavir Product Monograph when used in combination with these drugs.  Coadministration of atazanavir and TYBOST with atorvastatin is not recommended.  In cases where coadministration of atazanavir and TYBOST with rosuvastatin is necessary, start with the lowest recommended dose and titrate while monitoring for safety (eg, myopathy). Do not exceed 10 mg rosuvastatin daily and clinical monitoring is recommended. The risk of myopathy, including rhabdomyolysis, may be increased.
<b>Hormonal Contraceptives:</b>  norgestimate/ethinyl estradiol	↑ norgestimate ↔ ethinyl estradiol	No data are available to make recommendations on the use of atazanavir/cobicistat with oral contraceptives.  A drug interaction study between STRIBILD, which contains cobicistat, and a norgestimate/ethinyl estradiol-containing hormonal oral contraceptive resulted in decreased plasma concentrations of ethinyl estradiol and an increase in norgestimate. The effects of increases in the concentration of the progestational component norgestimate are not

Concomitant Drug Class: Drug Name	Effect on Concentration <sup>b</sup>	Clinical Comment
		<p>fully known and can include increased risk of insulin resistance, dyslipidemia, acne and venous thrombosis. The potential unknown risks and benefits associated with coadministration of norgestimate/ethinyl estradiol with TYBOST should be considered, particularly in women who have risk factors for these events.</p> <p>Alternative non-hormonal methods of contraception should be considered.</p>
<b>Immuno-suppressants:</b> cyclosporine rapamycin* sirolimus tacrolimus	↑ immuno-suppressants	Concentrations of these immunosuppressant agents may be increased when coadministered with TYBOST. Therapeutic monitoring is recommended upon coadministration with TYBOST.
<b>Narcotic Analgesics:</b> methadone         buprenorphine/naloxone	↔ R-methadone ↔ S-methadone         ↑ buprenorphine ↑ norbuprenorphine ↓ naloxone	<p>Methadone exposures are unaffected upon coadministration with cobicistat. No dose adjustment of methadone is required upon coadministration with TYBOST. However, careful clinical monitoring is recommended as the dose of methadone may need to be adjusted in some patients.</p> <p>Concentrations of buprenorphine and norbuprenorphine are modestly increased and concentrations of naloxone are modestly decreased when coadministered with cobicistat, with no changes on opioid pharmacodynamics. No dose adjustment of buprenorphine is required when coadministering with TYBOST. However, careful clinical monitoring is recommended as the dose of buprenorphine may need to be adjusted in some patients.</p>
<b>Neuroleptics:</b> perphenazine risperidone thioridazine*	↑ neuroleptics	Consider reducing the dose of the neuroleptic upon coadministration with TYBOST.
<b>Phosphodiesterase-5 Inhibitors:</b> sildenafil tadalafil vardenafil	↑ PDE5 inhibitors	PDE5 inhibitors are primarily metabolized by CYP3A. Coadministration with TYBOST may result in increased plasma concentrations of sildenafil, tadalafil and vardenafil, which may result in PDE5 inhibitor-associated adverse reactions. <p><b><u>For the treatment of pulmonary arterial hypertension:</u></b> Sildenafil is contraindicated (see <b>2 CONTRAINDICATIONS</b>).</p>

Concomitant Drug Class: Drug Name	Effect on Concentration <sup>b</sup>	Clinical Comment
		<p>Coadministration of TYBOST with tadalafil may increase concentrations of tadalafil due to CYP3A inhibition. Coadministration of TYBOST with tadalafil is not recommended.</p> <p>Caution should be exercised, including consideration of dose reduction, when coadministering TYBOST with tadalafil for the treatment of pulmonary arterial hypertension.</p> <p><b>For the treatment of erectile dysfunction:</b> it is recommended that a single dose of no more than sildenafil 25 mg in 48 hours, or no more than tadalafil 10 mg in 72 hours be coadministered with TYBOST. Vardenafil should not be coadministered with TYBOST.</p>
<b>Proton-Pump Inhibitors</b> omeprazole	↔ cobicistat	<p>No dose adjustment of cobicistat is required when atazanavir/cobicistat is coadministered with proton-pump inhibitors.</p> <p>Proton-pump inhibitors are expected to decrease atazanavir plasma concentration. Consult the atazanavir Product Monograph for atazanavir dosing recommendation when used concomitantly with proton-pump inhibitors.</p>
<b>Sedatives/hypnotics:</b> buspirone clorazepate diazepam estazolam* flurazepam zolpidem*	↑ sedatives/hypnotics	<p>Coadministration of TYBOST with these sedatives/hypnotics may increase concentrations of the sedative/hypnotic due to inhibition of CYP3A. Clinical monitoring is recommended when coadministering TYBOST with these sedatives/hypnotics, and dose reduction may be necessary.</p>

a. This table is not all inclusive.

b. ↑ = increase, ↓ = decrease, ↔ = no change

\* Not marketed in Canada.

## Assessment of Drug Interactions

The effects of coadministered drugs on the exposure of cobicistat are shown in Table 8. The effects of cobicistat on the exposure of coadministered drugs are shown in Table 9. For information regarding clinical recommendations, see **9 DRUG INTERACTIONS, Table 7 – Established and Other Potentially Significant Drug Interactions**.

In drug interaction studies conducted with cobicistat, there was no clinically significant interaction observed between cobicistat and the following drugs: famotidine or omeprazole (see **9 DRUG INTERACTIONS, Table 7 – Established and Other Potentially Significant Drug Interactions** for further guidance on clinical monitoring).

**Table 8. Drug Interactions: Changes in Pharmacokinetic Parameters for Cobicistat in the Presence of the Coadministered Drug<sup>a</sup>**



Coadministered Drug	Dose of Coadministered Drug (mg)	Cobicistat Dose (mg)	N	% Change of Cobicistat Pharmacokinetic Parameters (90% CI)		
				C <sub>max</sub>	AUC	C <sub>min</sub>
Atorvastatin	10 single dose	150 once daily <sup>b</sup>	16	↔	↔	↔
Carbamazepine	200 twice daily	150 once daily <sup>c</sup>	12	↓72 (↓76 to ↓67) <sup>d</sup>	↓84 (↓86 to ↓82) <sup>d</sup>	↓90 (↓93 to ↓86) <sup>d</sup>
Famotidine	40 once daily given 12 hours after elvitegravir	150 once daily <sup>c</sup>	10	↔	↔	↔
	40 once daily given simultaneously with elvitegravir		16	↔	↔	↔
Omeprazole	20 once daily given 2 hours before elvitegravir	150 once daily <sup>c</sup>	11	↔	↔	↔
	20 once daily given 12 hours after elvitegravir		11	↔	↔	↔
Rifabutin	150 once every other day	150 once daily <sup>c</sup>	12	↔ <sup>d</sup>	↔ <sup>d</sup>	↓66 <sup>d</sup> (↓74 to ↓54)
Rosuvastatin	10 single dose	150 once daily <sup>b</sup>	16	↔	↔	↔
		150 once daily <sup>c</sup>	10	↔ <sup>d</sup>	↔ <sup>d</sup>	↔ <sup>d</sup>

↑ = Increase; ↓ = Decrease; ↔ = No Effect

- All interaction studies conducted in healthy volunteers.
- Study was conducted in the presence of 300 mg atazanavir.
- Study was conducted in the presence of 150 mg elvitegravir.
- Comparison based on elvitegravir/cobicistat 150/150 mg once daily.

**Table 9. Drug Interactions: Changes in Pharmacokinetic Parameters for Coadministered Drugs in the Presence of Cobicistat<sup>a</sup>**

Coadministered Drug	Dose of Coadministered Drug (mg)	Cobicistat Dose (mg)	N	% Change of Coadministered Drug Pharmacokinetic Parameters (90% CI)		
				C <sub>max</sub>	AUC	C <sub>min</sub>
Atorvastatin	10 single dose	150 once daily <sup>b</sup>	16	↑1785 (↑1253 to ↑2527)	↑822 (↑658 to ↑1022)	NC
Carbamazepine	200 twice daily	150 once daily <sup>c</sup>	12	↑40 (↑32 to ↑49)	↑43 (↑36 to ↓52)	↑51 (↑41 to ↑62)
Carbamazepine-10,11-epoxide				↓27 (↓30 to ↓22)	↓35 (↓37 to ↓34)	↓41 (↓43 to ↓39)
Desipramine	50 single dose	150 once daily	8	↑24 (↑8 to ↑44)	↑65 (↑36 to ↑102)	NC
Digoxin	0.5 single dose	150 once daily	22	↑41 (↑29 to ↑55)	↔	NC
Drospirenone/ethinyl estradiol	3 drospirenone single dose	150 once daily <sup>b</sup>	14	↔	↑130 (↑100 to ↑164)	NC
	0.02 ethinyl estradiol single dose			↔	↔	NC
Efavirenz	600 single dose	150 once daily	17	↓13 (↓20 to ↓6)	↔	NC
R-Methadone	80-120 daily	150 once daily <sup>c</sup>	11	↔	↔	↔
S-Methadone				↔	↔	↔
Naloxone	4 - 6 once daily	150 once daily <sup>c</sup>	17	↓28 (↓39 to ↓15)	↓28 (↓41 to ↓13)	N/A
Norbuprenorphine	16–24 once daily	150 once daily <sup>c</sup>	17	↑12 (↓2 to ↑27)	↑35 (↑18 to ↑55)	↑66 (↑43 to ↑93)
				↑24 (↑3 to ↑49)	↑42 (↑22 to ↑67)	↑57 (↑31 to ↑88)
Norgestimate/ ethinyl estradiol	0.180/0.215/0.250 norgestimate once daily	150 once daily <sup>e</sup>	13	↑108 (↑100 to ↑117)	↑126 (↑115 to ↑137)	↑167 (↑143 to ↑192)
	0.025 ethinyl estradiol once daily			↔	↓25 (↓31 to ↓19)	↓44 (↓48 to ↓39)

Coadministered Drug	Dose of Coadministered Drug (mg)	Cobicistat Dose (mg)	N	% Change of Coadministered Drug Pharmacokinetic Parameters (90% CI)		
				C <sub>max</sub>	AUC	C <sub>min</sub>
Rifabutin	150 once every other day	150 once daily <sup>e</sup>	12	↔ <sup>d</sup>	↔ <sup>d</sup>	↔ <sup>d</sup>
25-O-desacetyl-rifabutin				↑384 <sup>d</sup> (↑309 to ↑474)	↑525 <sup>d</sup> (↑408 to ↑669)	↑394 <sup>d</sup> (↑304 to ↑504)
Rosuvastatin	10 single dose	150 once daily <sup>b</sup>	16	↑958 (↑772 to ↑1183)	↑242 (↑187 to ↑307)	NC
		150 single dose <sup>c</sup>	10	↑89 (↑48 to ↑142)	↑38 (↑14 to ↑67)	↑43 (↑8 to ↑89)

↑ = Increase; ↓ = Decrease; ↔ = No Effect; NC = Not Calculated

- All interaction studies conducted in healthy volunteers.
- Study was conducted in the presence of 300 mg atazanavir.
- Study was conducted in the presence of 150 mg elvitegravir.
- Comparison based on rifabutin 300 mg once daily.
- Study conducted with STRIBILD (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg).

## 9.5 Drug-Food Interactions

A food effect study was not conducted for TYBOST. However, a food effect study was conducted with STRIBILD, which contains TYBOST as one of its ingredients. This study found that, relative to fasting conditions, the administration of STRIBILD with a light meal (~373 kcal, 20% fat) or high-fat meal (~800 kcal, 50% fat) found that cobicistat exposures were unaffected by a light meal and although there was a modest decrease of 24% and 18% in C<sub>max</sub> and AUC respectively with a high-fat meal, no difference was observed in its pharmacoenhancing effect on elvitegravir.

In clinical studies, TYBOST was coadministered with atazanavir under fed conditions, in accordance with the atazanavir Product Monograph. It is recommended that TYBOST be administered with food.

## 9.6 Drug-Herb Interactions

Coadministration of St. John's wort (*Hypericum perforatum*), a potent CYP3A inducer, may significantly decrease TYBOST plasma concentrations, which may result in loss of therapeutic effect and development of resistance.

Coadministration of TYBOST with St. John's wort is contraindicated.

## 9.7 Drug-Laboratory Test Interactions

Interactions of TYBOST with laboratory tests have not been established.

## 10 CLINICAL PHARMACOLOGY

### 10.1 Mechanism of Action

Cobicistat is a selective, mechanism-based inhibitor of cytochrome P450 of the CYP3A subfamily. Inhibition of CYP3A-mediated metabolism by cobicistat enhances the systemic exposure of CYP3A substrates, such as atazanavir, where bioavailability is limited and half-life is shortened due to CYP3A-dependent metabolism.

### 10.2 Pharmacodynamics

#### Effects on Pharmacokinetic Enhancement

The effect of cobicistat on atazanavir pharmacokinetics was demonstrated in the pharmacokinetic substudy (N = 48) of the Phase 3 Study 114 in which HIV-1 infected subjects received atazanavir 300 mg + TYBOST 150 mg or atazanavir 300 mg + ritonavir 100 mg, both in combination with TRUVADA. The steady-state pharmacokinetic parameters of atazanavir were comparable when boosted with cobicistat versus ritonavir as shown in Table 10 (see **14 CLINICAL TRIALS**).

**Table 10. Pharmacokinetic Parameters (Mean ± SD) of Atazanavir in the Pharmacokinetic Substudy of Phase 3 trial (Study 114)**

<b>Atazanavir Pharmacokinetics Parameters</b>	<b>TYBOST-boosted Atazanavir + TRUVADA (N=22)</b>	<b>Ritonavir-boosted Atazanavir + TRUVADA (N=26)</b>
AUC <sub>tau</sub> (µg·h/mL)	46.13 ± 26.18	47.59 ± 24.39
C <sub>max</sub> (µg/mL)	3.91 ± 1.94	4.76 ± 1.94
C <sub>tau</sub> (µg/mL)	0.80 ± 0.72	0.85 ± 0.72

#### Antiviral Activity In Vitro

Cobicistat has no detectable antiviral activity against HIV-1, HBV, or HCV and does not antagonize the antiviral effect of HIV inhibitors.

#### Effects on Electrocardiogram

The electrocardiographic effects of cobicistat were determined in a study of 48 healthy adult subjects. Cobicistat did not prolong the QTcF interval at doses of 250 and 400 mg, providing exposures 2- and 4-fold above the recommended therapeutic dose, respectively. Prolongation of the PR interval was noted in subjects receiving cobicistat in the same study. The maximum mean (95% upper confidence bound) difference in PR from placebo after baseline-correction was 9.5 (12.1) ms for 250 mg dose and 20.2 (22.8) for 400-mg dose cobicistat. Because the proposed therapeutic dose of TYBOST is lower than the lowest dose studied in the thorough QT study, it is unlikely that treatment with TYBOST will result in clinically relevant PR prolongation.

In a human clinical study with 35 healthy subjects, echocardiograms performed at baseline and after receiving 150 mg cobicistat once daily for at least 15 days indicated no clinically significant change in left ventricular function.

## Effects on Serum Creatinine

The effect of TYBOST on serum creatinine was investigated in a Phase 1 study in subjects with normal renal function (eGFR  $\geq$  80 mL/min, N=18) and mild to moderate renal impairment (eGFR 50-79 mL/min, N=12). A statistically significant change of eGFR<sub>CG</sub> from baseline was observed after 7 days of treatment with cobicistat 150 mg among subjects with normal renal function ( $-9.9 \pm 13.1$  mL/min) and mild to moderate renal impairment ( $-11.9 \pm 7.0$  mL/min). These decreases in eGFR<sub>CG</sub> were reversible after cobicistat was discontinued. The actual glomerular filtration rate, as determined by the clearance of probe drug iohexol, was not altered from baseline following treatment of TYBOST among subjects with normal renal function and mild to moderate renal impairment, indicating cobicistat inhibits tubular secretion of creatinine, reflected as a reduction in eGFR<sub>CG</sub>, without affecting the actual glomerular filtration rate.

## 10.3 Pharmacokinetics

### Absorption

Following oral administration of TYBOST with food in HIV-1 infected patients, peak plasma concentrations were observed 3.5 hours post-dose for cobicistat. The steady-state mean C<sub>max</sub>, AUC<sub>tau</sub>, and C<sub>trough</sub> (mean  $\pm$  SD) following multiple doses of TYBOST in HIV-1 infected patients (N=68) were  $1.2 \pm 0.3$   $\mu$ g/mL,  $10.9 \pm 3.8$   $\mu$ g•h/mL, and  $0.07 \pm 0.07$   $\mu$ g/mL, respectively. Cobicistat exposures are non-linear and greater than dose-proportional over the range of 50 to 400 mg, consistent with a mechanism-based CYP3A inhibitor.

### Distribution

Cobicistat is 97% to 98% bound to human plasma proteins and the mean plasma to blood drug concentration ratio was 2.

### Metabolism

Cobicistat is metabolized via CYP3A (major)- and CYP2D6 (minor)-mediated oxidation and does not undergo glucuronidation. Following oral administration of [<sup>14</sup>C] cobicistat, 99% of circulating radioactivity in plasma was unchanged cobicistat. Low levels of metabolites are observed in urine and feces and do not contribute to the CYP3A inhibitory activity of cobicistat.

### Excretion

Following oral administration of [<sup>14</sup>C] cobicistat, 86% and 8.2% of the dose were recovered in feces and urine, respectively. The median terminal plasma half-life of cobicistat following administration of TYBOST is approximately 3 to 4 hours.

## Special Populations and Conditions

- **Pediatrics**

TYBOST is not recommended for pediatric administration. The pharmacokinetics of cobicistat have not been established in children (< 18 years).

- **Geriatrics**

The pharmacokinetics of cobicistat have not been fully evaluated in the elderly (> 65 years).

- **Sex**

No clinically relevant pharmacokinetic differences due to gender have been identified for cobicistat.

- **Ethnic Origin**

No clinically relevant pharmacokinetic differences due to ethnicity have been identified for cobicistat.

- **Hepatic Insufficiency**

Cobicistat is primarily metabolized and eliminated by the liver. A study of the pharmacokinetics of cobicistat was performed in non-HIV-1 infected subjects with moderate hepatic impairment (Child-Pugh Class B). No clinically relevant differences in cobicistat pharmacokinetics were observed between subjects with moderate impairment and healthy subjects. No dosage adjustment of TYBOST is necessary for patients with mild to moderate hepatic impairment. The effect of severe hepatic impairment (Child-Pugh Class C) on the pharmacokinetics of cobicistat has not been studied.

- **Hepatitis B and/or Hepatitis C Virus Coinfection**

The pharmacokinetics of cobicistat have not been fully evaluated in patients coinfecting with HIV-1 and hepatitis B and/or C.

- **Renal Insufficiency**

A study of the pharmacokinetics of cobicistat-boosted elvitegravir was performed in non-HIV-1 infected subjects with severe renal impairment (estimated creatinine clearance below 30 mL/min). No clinically relevant differences in cobicistat pharmacokinetics were observed between subjects with severe renal impairment and healthy subjects.

## **11 STORAGE, STABILITY AND DISPOSAL**

Store at room temperature 15 to 30°C (59-86°F).

- Keep container tightly closed.
- Dispense only in original container.
- Do not use if seal over bottle opening is broken or missing.
- Keep out of reach and sight of children.

## **12 SPECIAL HANDLING INSTRUCTIONS**

There are no special handling instructions.



## PART II. SCIENTIFIC INFORMATION

### 13 PHARMACEUTICAL INFORMATION

TYBOST is the brand name for cobicistat, a mechanism-based inhibitor of cytochrome P-450 (CYP) enzymes of the CYP3A family.

#### Drug Substance


**Common Name:** cobicistat (USAN)

**Chemical Name:** 1,3-Thiazol-5-ylmethyl [(2*R*,5*R*)-5-[[*(2S)*-2-[(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)amino]-4-(morpholin-4-yl)butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate

**Empirical Formula:** C<sub>40</sub>H<sub>53</sub>N<sub>7</sub>O<sub>5</sub>S<sub>2</sub>

**Molecular Weight:** 776.0

#### Structural Formula:



#### Physicochemical Properties:

**Description:** Cobicistat is adsorbed onto silicon dioxide. Cobicistat is a white to pale yellow solid.

**Solubility:** The solubility is approximately 0.1 mg/mL in water at 20°C. The partition coefficient (log P) is 4.3 (*n*-octanol/phosphate buffer pH 8.5) and the pKa is pKa1 = 1.8 (thiazole group), pKa2 = 2.5 (alkylthiazole group), pKa3 = 6.4 (morpholino group).

### 14 CLINICAL TRIALS

#### 14.1 Clinical Trials by Indication

##### In Combination with Atazanavir in HIV-1 Infected Adult Patients

The activity of cobicistat has been demonstrated in pharmacokinetic studies. In these pharmacokinetic studies, the exposure of atazanavir boosted with cobicistat 150 mg was



consistent with that observed with ritonavir 100 mg (see **10 CLINICAL PHARMACOLOGY, Effects on Pharmacokinetic Enhancement**).

The safety and efficacy of TYBOST with atazanavir was evaluated in a Phase 3, randomized, double-blind, active-controlled trial (Study 114) in antiretroviral treatment-naïve, HIV-1 infected subjects with baseline estimated creatinine clearance above 70 mL/min (N=692).

Randomization was stratified by screening HIV-1 RNA level ( $\leq 100,000$  copies/mL or  $> 100,000$  copies/mL). Virologic response rate was evaluated in both treatment arms and defined as achieving an undetectable viral load ( $< 50$  HIV-1 RNA copies/mL).

Demographic characteristics for Study 114 are presented in Table 11.

**Table 11. Study Treatment and Demographic Characteristics of Antiretroviral Treatment-naïve HIV-1 Infected Adult Subjects in Study 114**

Study	Dosage, Route of Administration	Demographics	
		Treatment Arm	Control Arm
GS-US-216-0114	Cobicistat-boosted atazanavir + TRUVADA (Treatment arm) or Ritonavir-boosted atazanavir + TRUVADA (Comparator arm)	<b>N=344</b>	<b>N=348</b>
		<b>Gender: n (%)</b> Male 287 (83.4) Female 57 (16.6) <b>Age: median (min-max)</b> 36 (19–62) <b>Race:</b> White – 198 (57.6) Black – 65 (18.9) Asian – 44 (12.8) Other – 37 (10.8) <b>Percentage of subjects with viral load &gt; 100,000 copies/mL:</b> 38.4% <b>Median baseline CD4<sup>+</sup> cell count (min-max), cells/mm<sup>3</sup>:</b> 348 (1-1075) <b>Percentage of subjects with CD4<sup>+</sup> cell count <math>\leq 200</math> cells/mm<sup>3</sup>:</b> 17.4%	<b>Gender: n (%)</b> Male 287 (82.5) Female 61 (17.5) <b>Age: median (min-max)</b> 37 (19–70) <b>Race:</b> White – 215 (61.8) Black – 63 (18.1) Asian – 37 (10.6) Other – 33 (9.5) <b>Percentage of subjects with viral load &gt; 100,000 copies/mL:</b> 41.1% <b>Median baseline CD4<sup>+</sup> cell count (min-max), cells/mm<sup>3</sup>:</b> 341 (10-1455) <b>Percentage of subjects with CD4<sup>+</sup> cell count <math>\leq 200</math> cells/mm<sup>3</sup>:</b> 16.4%

Treatment outcomes at 48 weeks are presented in Table 12.

**Table 12. Virologic Outcome of Randomized Treatment of Study 114 at Week 48<sup>a</sup>**

	<b>TYBOST-boosted Atazanavir + TRUVADA (N=344)</b>	<b>Ritonavir-boosted Atazanavir + TRUVADA (N=348)</b>
<b>Virologic Success</b>		
HIV-1 RNA < 50 copies/mL	85% (293)	87% (304)
Treatment Difference	-2.2% (95% CI = -7.4%, 3.0%)	
<b>Virologic Failure<sup>b</sup></b>	6% (20)	4% (14)
<b>No Virologic Data at Week 48 Window</b>	9% (31)	9% (30)
Discontinued Study Drug Due to AE or Death <sup>c</sup>	6% (22)	7% (23)
Discontinued Study Drug Due to Other Reasons and Last Available HIV-1 RNA < 50 copies/mL <sup>d</sup>	3% (9)	2% (7)
Missing Data During Window but on Study Drug	0%	0%

- Week 48 window is between Day 309 and 378 (inclusive).
- Includes subjects who had  $\geq 50$  copies/mL in the Week 48 window, subjects who discontinued early due to lack or loss of efficacy, subjects who discontinued for reasons other than an adverse event, death or lack or loss of efficacy and at the time of discontinuation had a viral value of  $\geq 50$  copies/mL.
- Includes subjects who discontinued due to adverse event or death at any time point from Day 1 through the Week 48 window resulting in no virologic data on treatment during the specified window.
- Includes subjects who discontinued for reasons other than an adverse event, death or lack or loss of efficacy, eg, withdrew consent, loss to follow-up, etc.

TYBOST-boosted atazanavir + TRUVADA was non-inferior in achieving HIV-1 RNA < 50 copies/mL when compared to ritonavir-boosted atazanavir + TRUVADA.

In Study 114, the mean increase from baseline in CD4+ cell count at Week 48 was 213 cells/mm<sup>3</sup> in patients receiving TYBOST-boosted atazanavir + TRUVADA and 219 cells/mm<sup>3</sup> in patients receiving ritonavir-boosted atazanavir + TRUVADA.

## 15 MICROBIOLOGY

### Antiviral Activity

Cobicistat has no detectable antiviral activity against HIV-1, HBV, or HCV and does not antagonize the antiviral effect of HIV inhibitors.

### Resistance

In an analysis of treatment-failure subjects in Study 114 through Week 48, evaluable genotypic data from paired baseline and treatment-failure isolates were available for 11 of the 12 virologic failures in the TYBOST group. Among the 11 subjects, 2 developed the emtricitabine-associated resistance substitution M184V. No subject developed the tenofovir-associated resistance substitution K65R or any primary resistance substitution associated with protease inhibitors. In

the ritonavir group, evaluable genotypic data were available for all 12 virologic failures and no patient had emergent resistance to any component of the regimen (see **14 CLINICAL TRIALS**).

## **16 NON-CLINICAL TOXICOLOGY**

### **Carcinogenicity:**

In a long-term carcinogenicity study in mice, no drug-related increases in tumor incidence were observed at doses up to 50 and 100 mg/kg/day (males and females, respectively). Cobicistat exposures at these doses were approximately 7 (male) and 16 (females) times the human systemic exposure at the therapeutic daily dose. In a long-term carcinogenicity study of cobicistat in rats, an increased incidence of follicular cell adenomas and/or carcinomas in the thyroid gland was observed at doses of 25 and 50 mg/kg/day in males, and at 30 mg/kg/day in females. The follicular cell findings are considered to be rat-specific, secondary to hepatic microsomal enzyme induction and thyroid hormone imbalance, and not relevant for humans. At the highest doses tested in the rat carcinogenicity study, systemic exposures were approximately 2 times the human systemic exposure at the therapeutic daily dose.

### **Cardiovascular**

*Ex vivo* rabbit studies and *in vivo* dog studies suggested that cobicistat has a low potential for QT prolongation, and may slightly prolong the PR interval and decrease left ventricular function at mean concentrations at least 10-fold higher than the human exposure at the recommended 150 mg daily dose (see **10 CLINICAL PHARMACOLOGY, Effects on Electrocardiogram**).

### **Genotoxicity:**

Cobicistat was not genotoxic in the reverse mutation bacterial test (Ames test), mouse lymphoma or rat micronucleus assays.

### **Reproductive and Developmental Toxicology:**

Reproductive studies were conducted in rats and rabbits. Animal studies did not indicate direct or indirect harmful effects of cobicistat with respect to pregnancy, fetal development, parturition, or postnatal development. There were no effects on mating and fertility parameters.

Studies in animals have shown no evidence of teratogenicity or an effect on reproductive function. In offspring from rat and rabbit dams treated with cobicistat during pregnancy, there were no toxicologically significant effects on developmental endpoints. The exposures at the embryo-fetal NOAELs in rats and rabbits were respectively 1.4 and 3.3 times higher than the exposure in humans at the recommended daily dose of 150 mg.

Cobicistat did not affect fertility in male or female rats at daily exposures (AUC) approximately 3.3-fold higher than human exposures at the recommended 150 mg daily dose.

Fertility was normal in the offspring of rats exposed daily from before birth (*in utero*) through sexual maturity at daily exposures (AUC) approximately 0.9-fold human exposures at the recommended 150 mg daily dose.



## PATIENT MEDICATION INFORMATION

### READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

#### TYBOST®

#### cobicistat tablets

Read this carefully before you start taking **Tybost** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **Tybost**.

#### What is Tybost used for?

**Tybost** is used with another medicine called atazanavir (Reyataz®) to treat Human Immunodeficiency Virus-1 (HIV) infection in adults. The safety and effect of **Tybost** has not been established in children under age 18.

#### How does Tybost work?

**Tybost** is a medicine called a pharmacokinetic enhancer (or “booster”). **Tybost** slows the enzyme that breaks down atazanavir (Reyataz) in the body. This causes a “boost” or an increase of atazanavir levels in the blood. Atazanavir will then stay in the body for longer. **Tybost** does not directly treat your HIV infection.

#### What are the ingredients in Tybost?

Medicinal ingredients: cobicistat.

Non-medicinal ingredients: croscarmellose sodium, iron oxide yellow, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, silicon dioxide, sunset yellow FCF (FD&C Yellow #6) aluminum lake, talc, titanium dioxide.

#### Tybost comes in the following dosage forms:

Tablets: 150 mg. The tablets are orange, round, biconvex, and film-coated, debossed with “GSI” on one side and plain-faced on the other side.

#### Do not use Tybost if:

- You are allergic to **Tybost** or any of its ingredients. (Read also “**What are the ingredients in Tybost?**” above.)
- You are taking any medicines listed in this pamphlet under “**Drugs that must not be taken with Tybost**” or “**If you are taking Tybost, you should not take:**” sections.

**To help avoid side effects and ensure proper use, talk to your healthcare professional before you take Tybost. Talk about any health conditions or problems you may have, including if you:**

- Are taking another protease inhibitor. **Tybost** taken with atazanavir should not be used with another antiviral medicine that requires boosting.
- Have other medical conditions. Let your doctor know if you have other medical conditions, especially liver problems (including hepatitis B or C virus infection), or kidney problems.

#### Other warnings you should know about:

Redistribution or accumulation of body fat has been seen in people taking antiretroviral medications such as **Tybost**. This can include central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting (loss of muscle), facial wasting (loss of fat in face), breast enlargement, and “cushingoid appearance”.

Using **Tybost** with atazanavir does not cure HIV infection or AIDS. The long-term effects of **Tybost** are not known at this time. People taking **Tybost** with atazanavir (Reyataz) may still get opportunistic infections or other conditions that happen with HIV infection. Opportunistic infections are infections that develop because the immune system is weak. Some of these conditions are pneumonia, herpes virus infections, and Mycobacterium avium complex (MAC) infections. **It is very important that you see your doctor regularly while taking Tybost.**

Using **Tybost** with atazanavir (Reyataz) has not been shown to reduce the risk of passing HIV to others through sexual contact or blood contamination. Continue to practice safe sex. Use latex or polyurethane condoms to lower the chance of sexual contact with any body fluids such as semen, vaginal secretions, or blood. Do not re-use or share needles.

### **Pregnancy:**

If you are pregnant or plan to become pregnant, talk to your doctor before you take this medicine. The effects of **Tybost** during pregnancy are not known. Avoid pregnancy while taking **Tybost**. Tell your doctor if you become pregnant while taking **Tybost**:

**Pregnancy Registry:** There is a pregnancy registry for women who take antiviral medicines during pregnancy. This registry collects information about your health and your baby’s health. If you become pregnant while taking **Tybost**, talk with your doctor about taking part in this registry.

### **Breastfeeding:**

#### ***If you are breast-feeding or plan to breast-feed:***

Do not breast-feed if you have HIV because of the chance of passing the HIV virus to your baby. It is not known if **Tybost** can pass through your breast milk and harm your baby. If you are a woman who has or will have a baby, talk with your doctor about the best way to feed your baby.

#### ***If you are taking other medicines:***

Some medicines can interact when taken together, including prescription and non-prescription medicines, herbal products and dietary supplements (see “**Drugs that must not be taken with Tybost**” and “**If you are taking Tybost, you should not take:**” section

**Tybost** should not be used in combination with another medicine called quetiapine. This is because serious and possibly life-threatening reactions can occur. This includes severe sedation and coma. If it is necessary for you to take **Tybost** with quetiapine your doctor may need to monitor you and adjust the dose of quetiapine.

**Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.**

### **Drugs that must not be taken with Tybost (contraindicated):**

- alfuzosin hydrochloride (Xatral®)
- apixaban (Eliquis®), rivaroxaban (Xarelto®)

- astemizole\* (Hismanal<sup>®</sup>) or terfenadine\* (Seldane<sup>®</sup>)
  - carbamazepine (Tegretol<sup>®</sup>)
  - cisapride\* (Propulsid<sup>®</sup>)
  - colchicine
  - dronedarone (Multaq<sup>®</sup>)
  - drospirenone/ ethinyl estradiol (Yaz<sup>®</sup>)
  - elbasvir/grazoprevir (Zepatier<sup>®</sup>)
  - ergot-containing medicines: dihydroergotamine, ergonovine, ergotamine, methylergonovine, such as Migranal<sup>®</sup> and others.
  - indinavir\* (Crixivan<sup>®</sup>)
  - irinotecan
  - lomitapide (Juxtapid<sup>™</sup>)
  - lovastatin\* (Advicor<sup>®</sup>, Mevacor<sup>®</sup>)
  - lurasidone (Latuda<sup>®</sup>)
  - midazolam\* (Versed<sup>®</sup>), when taken by mouth
  - nevirapine
  - phenobarbital, phenytoin (Dilantin<sup>®</sup>)
  - pimozide (Orap<sup>®</sup>)
  - rifampin (Rofact<sup>®</sup>)
  - ranolazine\* (Ranexa<sup>®</sup>)
  - salmeterol (Serevent<sup>®</sup>)
  - sildenafil (Revatio<sup>®</sup>), when used for treating lung problems
  - simvastatin (Zocor<sup>®</sup>)
  - St. John's Wort (*Hypericum perforatum*) or products containing St. John's Wort
  - triazolam
- \*Not available in Canada

**If you are taking Tybost, you should not take:**

- antiplatelets such as clopidogrel (Plavix<sup>®</sup>)
- medications that may affect your kidneys and have not discussed this with your doctor.
- any other HIV protease inhibitors: eg, saquinavir (Invirase<sup>®</sup>), tipranavir (Aptivus<sup>®</sup>), or fosamprenavir (Telzir<sup>®</sup>), lopinavir (Kaletra<sup>®</sup>), darunavir (Prezista<sup>®</sup>).
- other medicines that contain cobicistat (GENVOYA<sup>®</sup>, Prezcobix<sup>®</sup>, STRIBILD<sup>®</sup>, Symtuza<sup>®</sup>).
- ritonavir (Kaletra<sup>®</sup>, Norvir<sup>®</sup>)

**Tell your doctor before using Tybost if you are taking these drugs:**

The dosage of **Tybost** or the dosage of the following drugs may need to be changed:

- antivirals such as didanosine, delavirdine, efavirenz, maraviroc
- antiarrhythmic drugs (for the heart) such as amiodarone, bepridil, flecainide (Tambocor<sup>®</sup>), quinidine
- anticancer drugs such as dasatinib, nilotinib, vinblastine, vincristine
- anticoagulants such as warfarin, dabigatran (Pradaxa<sup>®</sup>), edoxaban (Lixiana<sup>®</sup>)
- anticonvulsant drugs such as clonazepam
- antidepressants such as trazadone, desipramine
- antifungals such as itraconazole (Sporanox<sup>®</sup>), ketoconazole (Nizoral<sup>®</sup>), voriconazole (Vfend<sup>®</sup>)
- antimycobacterials such as rifabutin, rifapentine
- antipsychotics such as risperidone, pimozide, perphenazine, quetiapine

- beta-blockers such as timolol, metoprolol (Lopresor®)
  - calcium channel blockers (for the heart) such as amlodipine (Norvasc®), felodipine, verapamil
  - corticosteroids such as betamethasone, budesonide, fluticasone (Flonase®), mometasone, and triamcinolone
  - HCV protease inhibitors such as boceprevir\*
  - H<sub>2</sub> receptor antagonists (acid reducers) such as famotidine
  - HMG-COA reductase inhibitors (lowers cholesterol) such as atorvastatin and rosuvastatin
  - hormonal contraceptives such as norgestimate/ethinyl estradiol
  - immunosuppressants such as cyclosporine (Neoral®), sirolimus (Rapamune®) and tacrolimus (Prograf®)
  - phosphodiesterase -5 inhibitors (for erectile dysfunction) such as sildenafil (Viagra®), tadalafil (Cialis®, Adcirca®) and vardenafil (Levitra®)
  - proton pump inhibitors (acid reducers) such as omeprazole
- \*Not available in Canada

### How to take Tybost:

Together with your doctor, you need to decide whether **Tybost** is right for you.

Stay under a doctor's care when taking **Tybost**. Do not change your treatment or stop treatment without first talking with your doctor.

Take **Tybost** every day exactly as your doctor prescribed it. Follow the directions from your doctor, exactly as written on the label. Set up a dosing schedule and follow it carefully.

When your **Tybost** supply starts to run low, get more from your doctor or pharmacy. This is very important because the amount of virus in your blood may increase if the medicine is stopped for even a short time. If **Tybost** is not taken regularly, as prescribed, the virus may become harder to treat.

Only take medicine that has been prescribed specifically for you. Do not give **Tybost** to others or take medicine prescribed for someone else. Do not use if seal over bottle opening is broken or missing.

### Usual dose:

The usual dose of **Tybost** is one tablet orally (by mouth) once a day. Swallow with plenty of water.

Take **Tybost** at the same time as atazanavir (Reyataz) with food. Taking **Tybost** with food helps get the right amount of medicine in your body.

### Overdose:

If you think you, or a person you are caring for, have taken too much **Tybost**, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

### Missed Dose:

It is important that you do not miss any doses.

If you miss a dose of **Tybost** by less than 12 hours, take the missed dose right away. Then take



your next dose as usual with atazanavir (Reyataz). If you miss a dose of **Tybost** by more than 12 hours, wait and take the next dose of **Tybost** with atazanavir at your usual time.

If you miss a dose of atazanavir, follow the advice given in the Consumer Information Leaflet for this medicine. If you miss a dose of **Tybost** and atazanavir, follow the advice given in the Consumer Information Leaflet for atazanavir and take **Tybost** at the same time as atazanavir.

**Do not** take 2 doses at the same time. Call your doctor or pharmacist if you are not sure what to do. Always take **Tybost** with food.

### **What are possible side effects from using Tybost?**

These are not all the possible side effects you may have when taking **Tybost**. If you experience any side effects not listed here, tell your healthcare professional.

The most common side effect seen in studies which included **Tybost** is yellowing of the skin, nausea and rash. Other side effects include yellowing of the eyes and an increase in the level of bilirubin in the blood (hyperbilirubinemia).

Changes in your immune system (Immune Reconstitution Inflammatory Syndrome) can happen when you start taking HIV medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time, or you could develop an autoimmune disease in which your immune system reacts against your own body (eg, Graves' disease [which affects the thyroid gland], Guillain-Barré syndrome [which affects the nervous system] or polymyositis [which affects the muscles] and it may develop at any time, sometimes months later after the start of HIV therapy). Sometimes symptoms can be severe, so if you develop high temperature (fever), joint or muscle pain, redness, rash, swelling or fatigue, or any new symptoms, contact your doctor right away.

For more information on the side effects of atazanavir (Reyataz), see the Consumer Information Leaflet for atazanavir.

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

### **Reporting Side Effects**

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

### **Storage:**

- Keep **Tybost** and all other medications out of reach and sight of children.
- **Tybost** should be stored at room temperature, 15 to 30°C (59-86°F). It should remain stable until the expiration date printed on the label.
- Do not keep your medicine in places that are too hot or cold.
- Do not keep medicine that is out of date or that you no longer need. If you throw any medicines away make sure that children will not find them.
- Keep **Tybost** in its original container and keep the container tightly closed.

**If you want more information about Tybost:**

- Talk to your healthcare professional.
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website ([www.gilead.ca](http://www.gilead.ca)), or by calling 1-800-207-4267.

This leaflet was prepared by Gilead Sciences Canada, Inc.

Last Revised August 17, 2021

**Gilead Sciences, Inc.**  
Foster City, CA 94404  
USA

**Gilead Sciences Canada, Inc.**  
Mississauga, ON  
L5N 2W3

GENVOYA<sup>®</sup>, STRIBILD<sup>®</sup>, TRUVADA<sup>®</sup>, and TYBOST<sup>®</sup> are trademarks of Gilead Sciences, Inc. or its related companies.

All other marks referenced herein are the property of their respective owners.

© 2021 Gilead Sciences, Inc. All rights reserved.

